Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma

Lauren E. Haydu; Serigne Lo; Jennifer L. McQuade; Rodabe N. Amaria; Jennifer A. Wargo; Merrick I. Ross; Janice N. Cormier; Anthony Lucci; Jeffrey E. Lee; Sherise D. Ferguson; Robyn P.M. Saw; Andrew J. Spillane; Kerwin F. Shannon; Jonathan R. Stretch; Patrick Hwu; Sapna P. Patel; Adi Diab; Michael K. Wong; Isabella C. Glitza Oliva; Hussein A. Tawbi; Matteo S. Carlino; Alexander M. Menzies; Georgina V. Long; Alexander J. Lazar; Michael T. Tetzlaff; Richard A Scolyer; Jeffrey E. Gershenwald; John F. Thompson; Michael A. Davies

doi:10.1200/jco.19.01508

Abstract

1 min read

Similar rates of CNS metastasis were observed in 2 large, geographically distinct cohorts of patients with stage III melanoma. The results highlight the importance of primary tumor mitotic rate. Furthermore, they provide a framework for developing evidence-based surveillance strategies and evaluating the impact of contemporary adjuvant therapies on the risk of CNS metastasis development.

Related publications

Article2019

OTHR-08. PREDICTION OF RISK OF CENTRAL NERVOUS SYSTEM METASTASIS FOR AJCC 8TH EDITION STAGE III MELANOMA PATIENTS

Lauren E. Haydu, Serigne Lo, Jennifer L. McQuade, Isabella C. Glitza, Hussein A. Tawbi, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long, Alexander J. Lazar, Michael T. Tetzlaff, Richard A Scolyer, Jeffrey E. Gershenwald, John F. Thompson, Michael A. Davies

Article2024

Incidence and risk factors for central nervous system (CNS) metastasis (met) in patients (pts) with stage III melanoma treated with adjuvant (ADJ) anti-PD1 immunotherapy (IMT).

Michael A. Davies, Julie M. Simon, Alexander M. Menzies, Denái R. Milton, James S. Wilmott, Debora Alejandra Ledesma, Elizabeth M. Burton, Sherise D. Ferguson, Hussein A. Tawbi, Jeffrey E. Gershenwald, Carlos A. Torres‐Cabala, Isabella Claudia Glitza, Alexander J. Lazar, Robyn P.M. Saw, Andrew J. Spillane, Matteo S. Carlino, Richard A Scolyer, Georgina V. Long

Article2017

Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

Jeffrey E. Gershenwald, Richard A Scolyer, Kenneth R. Hess, Vernon K. Sondak, Georgina V. Long, Merrick I. Ross, Alexander J. Lazar, Mark B. Faries, John M. Kirkwood, Grant A. McArthur, Lauren E. Haydu, Alexander M.M. Eggermont, Keith T. Flaherty, Charles M. Balch, John F. Thompson

Article2023

External validation and nomogram for risk factors of CNS metastasis in patients with clinically localized melanoma.

Merve Hasanov, Denái R. Milton, Serigne Lo, Jeffrey E. Gershenwald, Julie M. Simon, Georgina V. Long, Richard A Scolyer, Michael A. Davies

Article2025

Rational use of adjuvant anti-PD-1: Multi-omics model of recurrence in stage III melanoma.

Tuba N. Gide, Nurudeen A. Adegoke, Michael Xie, Yizhe Mao, Grace H. Attrill, Nigel Maher, Robyn P.M. Saw, Ismael A. Vergara, Matteo S. Carlino, Serigne Lo, Inês Pires da Silva, Jorja Braden, Alexander M. Menzies, Richard A Scolyer, Georgina V. Long, James S. Wilmott